Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04921943 · ClinicalTrials.gov registry record · Phase 4
Hypertonic Saline for MAC
A Phase 4 study of Nontuberculous Mycobacterial Lung Disease and Nontuberculous Mycobacterium Infection, sponsored by Oregon Health and Science University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
- 3
- Study locations
NCT04921943: Recruiting Phase 4 study of Nontuberculous Mycobacterial Lung Disease and Nontuberculous Mycobacterium Infection, sponsored by Oregon Health and Science University.
NCT04921943 is a Phase 4 study of Nontuberculous Mycobacterial Lung Disease and Nontuberculous Mycobacterium Infection that is actively recruiting participants, run by Oregon Health and Science University. The registered enrollment target is 50 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (90% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04921943, a Phase 4 study of Nontuberculous Mycobacterial Lung Disease and Nontuberculous Mycobacterium Infection, is actively recruiting participants, sponsored by Oregon Health and Science University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
- 3
- Study locations
Study Summary
The MAC-HS study is a testing whether hypertonic saline helps improve symptoms and clearance of mycobacteria in patients with M. avium complex lung infections.
Primary Outcome
At least two negative AFB cultures on different days.
Conditions Studied
Interventions
- DRUG Azithromycin
- DRUG Hypertonic saline
- DRUG Ethambutol
- DRUG Rifampin
Study Locations (3)
New York
- NYU Langone Health - New York
Oregon
- Oregon Health & Science University - Portland
Ontario
- University Health Network - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2021-05-18 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 4 |
What NCT04921943 shows while recruiting
NCT04921943 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (90% lower).
The record links to 2 conditions, with Nontuberculous Mycobacterial Lung Disease appearing as the primary indexed condition, and to 4 interventions - of which Azithromycin is the first listed.
NCT04921943 reports a single indexed study location in New York, Oregon, Ontario.
Frequently Asked Questions
What is clinical trial NCT04921943 about?
NCT04921943 is a clinical study titled "Hypertonic Saline for MAC". The MAC-HS study is a testing whether hypertonic saline helps improve symptoms and clearance of mycobacteria in patients with M. avium complex lung infections.
What is the current status of trial NCT04921943?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2021-05-18. Estimated completion is 2025-12-31.
What conditions does trial NCT04921943 study?
This clinical trial studies the following conditions: Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterium Infection.
What interventions are being tested in trial NCT04921943?
The interventions under investigation include: Azithromycin (DRUG), Hypertonic saline (DRUG), Ethambutol (DRUG), Rifampin (DRUG).
Who is sponsoring clinical trial NCT04921943?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04921943 being conducted?
This trial has 3 study locations across New York, Oregon, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nontuberculous Mycobacterial Lung Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04921943's enrollment target sits among peer trials
50 1255th of 2000 higher than 679 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI